Competing interests
Cergentis
SL receives research funding to her institution from Agendia, AstraZeneca, Eurocept-pharmaceuticals, Genentech, GSK (formerly Tesaro), Immunomedics, Merck, Novartis, Roche; has acted as a consultant (not compensated) for Cergentis and Philips Health; has acted as a consultant (paid to her institution) for AstraZeneca and IBM; has received educational funding to her institution from Bayer and Daiichi-Sankyo. In addition, SL has a patent UN23A01/P-EP pending. VR and WvH received unrestricted research grants from Agendia BV and Intuitive BV, outside the scope of the current research. The other authors declare that they have no conflict of interest.